John C. Bell Center for Innovative Cancer Research Ottawa Hospital Research Institute (OHRI) Biography Publications Institution JoVE Articles John C. Bell has not added a biography. If you are John C. Bell and would like to personalize this page please email our Author Liaison for assistance. Publications Electrochemical Differentiation of Epitope-Specific Aptamers Analytical Chemistry. Feb, 2012 | Pubmed ID: 22324738 Aptamer-Based Viability Impedimetric Sensor for Viruses Analytical Chemistry. Feb, 2012 | Pubmed ID: 22303883 ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic Molecular Therapy : the Journal of the American Society of Gene Therapy. Jan, 2012 | Pubmed ID: 22273579 Electrochemical Sensing of Aptamer-facilitated Virus Immunoshielding Analytical Chemistry. Feb, 2012 | Pubmed ID: 22242920 Oncolytic Viruses: Smart Therapeutics for Smart Cancers Future Oncology (London, England). Jan, 2012 | Pubmed ID: 22149027 The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers Molecular Therapy : the Journal of the American Society of Gene Therapy. Dec, 2011 | Pubmed ID: 22186794 Sensitivity of Cervical Carcinoma Cells to Vesicular Stomatitis Virus-induced Oncolysis: Potential Role of Human Papilloma Virus Infection International Journal of Cancer. Journal International Du Cancer. Dec, 2011 | Pubmed ID: 22173567 Suppression of PKR Promotes Network Excitability and Enhanced Cognition by Interferon-γ-mediated Disinhibition Cell. Dec, 2011 | Pubmed ID: 22153080 Interfering with Tumor Pathways That Augment Viral Oncolysis Molecular Therapy : the Journal of the American Society of Gene Therapy. Dec, 2011 | Pubmed ID: 22134743 A Selectable and Excisable Marker System for the Rapid Creation of Recombinant Poxviruses PloS One. 2011 | Pubmed ID: 21931792 Intravenous Delivery of a Multi-mechanistic Cancer-targeted Oncolytic Poxvirus in Humans Nature. Sep, 2011 | Pubmed ID: 21886163 A Mechanistic Proof-of-concept Clinical Trial with JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients with Metastatic Melanoma Molecular Therapy : the Journal of the American Society of Gene Therapy. Oct, 2011 | Pubmed ID: 21772252 Targeted and Armed Oncolytic Poxviruses for Cancer: The Lead Example of JX-594 Current Pharmaceutical Biotechnology. Jul, 2011 | Pubmed ID: 21740365 Viral Quantitative Capillary Electrophoresis for Counting Intact Viruses Analytical Chemistry. Jul, 2011 | Pubmed ID: 21599011 Chromosomal Position Effects Are Linked to Sir2-mediated Variation in Transcriptional Burst Size Biophysical Journal. May, 2011 | Pubmed ID: 21575565 Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide Molecular Therapy : the Journal of the American Society of Gene Therapy. Jun, 2011 | Pubmed ID: 21505424 Sequential Therapy with JX-594, a Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy Molecular Therapy : the Journal of the American Society of Gene Therapy. Jun, 2011 | Pubmed ID: 21427706 Targeting Tumor Vasculature with an Oncolytic Virus Molecular Therapy : the Journal of the American Society of Gene Therapy. May, 2011 | Pubmed ID: 21364541 Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors PloS One. 2010 | Pubmed ID: 21283510 Efficacy and Safety/toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma Molecular Therapy : the Journal of the American Society of Gene Therapy. Nov, 2010 | Pubmed ID: 20808290 Oncolytic Targeting of Renal Cell Carcinoma Via Encephalomyocarditis Virus EMBO Molecular Medicine. Jul, 2010 | Pubmed ID: 20623734 Identification of Genetically Modified Maraba Virus As an Oncolytic Rhabdovirus Molecular Therapy : the Journal of the American Society of Gene Therapy. Aug, 2010 | Pubmed ID: 20551913 Navigating the Clinical Development Landscape for Oncolytic Viruses and Other Cancer Therapeutics: No Shortcuts on the Road to Approval Cytokine & Growth Factor Reviews. Apr-Jun, 2010 | Pubmed ID: 20472490 A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers Molecular Therapy : the Journal of the American Society of Gene Therapy. Jun, 2010 | Pubmed ID: 20389287 Double Trouble for Tumours: Exploiting the Tumour Microenvironment to Enhance Anticancer Effect of Oncolytic Viruses Cytokine & Growth Factor Reviews. Apr-Jun, 2010 | Pubmed ID: 20338801 Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing Molecular Therapy : the Journal of the American Society of Gene Therapy. May, 2010 | Pubmed ID: 20234341 United Virus: the Oncolytic Tag-team Against Cancer! Cytokine & Growth Factor Reviews. Apr-Jun, 2010 | Pubmed ID: 20227326 Novel Oncolytic Viruses: Riding High on the Next Wave? Cytokine & Growth Factor Reviews. Apr-Jun, 2010 | Pubmed ID: 20219409 Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity Molecular Therapy : the Journal of the American Society of Gene Therapy. May, 2010 | Pubmed ID: 20160706 Vesicular Stomatitis Virus Oncolysis is Potentiated by Impairing MTORC1-dependent Type I IFN Production Proceedings of the National Academy of Sciences of the United States of America. Jan, 2010 | Pubmed ID: 20080710 Intravenously Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts in Nude Mice PloS One. 2010 | Pubmed ID: 20066051 Intelligent Design: Combination Therapy with Oncolytic Viruses Molecular Therapy : the Journal of the American Society of Gene Therapy. Feb, 2010 | Pubmed ID: 20029399 Down-regulation of Type I Interferon Receptor Sensitizes Bladder Cancer Cells to Vesicular Stomatitis Virus-induced Cell Death International Journal of Cancer. Journal International Du Cancer. Aug, 2010 | Pubmed ID: 19957332 Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models Journal of Virology. Jan, 2010 | Pubmed ID: 19906926 Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2009 | Pubmed ID: 19351762 Diplomatic Immunity: Turning a Foe into an Ally Current Opinion in Molecular Therapeutics. Feb, 2009 | Pubmed ID: 19169955 The P14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis Journal of Virology. Jan, 2009 | Pubmed ID: 18971262 MicroRNAs Fine-tune Oncolytic Viruses Nature Biotechnology. Dec, 2008 | Pubmed ID: 19060871 Chemical Targeting of the Innate Antiviral Response by Histone Deacetylase Inhibitors Renders Refractory Cancers Sensitive to Viral Oncolysis Proceedings of the National Academy of Sciences of the United States of America. Sep, 2008 | Pubmed ID: 18815361 Development of Targeted Oncolytic Virotherapeutics Through Translational Research Expert Opinion on Biological Therapy. Sep, 2008 | Pubmed ID: 18694356 Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSVDelta51) Combined with Radiation for Nasopharyngeal Carcinoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2008 | Pubmed ID: 18676763 A Let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication Molecular Therapy : the Journal of the American Society of Gene Therapy. Aug, 2008 | Pubmed ID: 18560417 Oncolytic Vesicular Stomatitis Viruses Are Potent Agents for Intravesical Treatment of High-risk Bladder Cancer Cancer Research. Jun, 2008 | Pubmed ID: 18559493 Translation of Targeted Oncolytic Virotherapeutics from the Lab into the Clinic, and Back Again: a High-value Iterative Loop Molecular Therapy : the Journal of the American Society of Gene Therapy. Jun, 2008 | Pubmed ID: 18500240 Use of a Targeted Oncolytic Poxvirus, JX-594, in Patients with Refractory Primary or Metastatic Liver Cancer: a Phase I Trial The Lancet Oncology. Jun, 2008 | Pubmed ID: 18495536 Complex Rearrangement of Chromosomes 19, 21, and 22 in Ewing Sarcoma Involving a Novel Reciprocal Inversion-insertion Mechanism of EWS-ERG Fusion Gene Formation: a Case Analysis and Literature Review Cancer Genetics and Cytogenetics. Mar, 2008 | Pubmed ID: 18295659 Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2008 | Pubmed ID: 18281557 Translational Control of the Innate Immune Response Through IRF-7 Nature. Mar, 2008 | Pubmed ID: 18272964 Innate Immunity, Tumor Microenvironment and Oncolytic Virus Therapy: Friends or Foes? Current Opinion in Molecular Therapeutics. Feb, 2008 | Pubmed ID: 18228179 Matrix Protein Mediated Shutdown of Host Cell Metabolism Limits Vesicular Stomatitis Virus-induced Interferon-alpha Responses to Plasmacytoid Dendritic Cells Immunobiology. 2007 | Pubmed ID: 18086387 Intercellular Trafficking of VP22, a Herpes Simplex Virus Type 1 Tegument Protein Iranian Biomedical Journal. Jan, 2007 | Pubmed ID: 18051705 Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow Molecular Therapy : the Journal of the American Society of Gene Therapy. Sep, 2007 | Pubmed ID: 17579581 Radioiodide Imaging and Radiovirotherapy of Multiple Myeloma Using VSV(Delta51)-NIS, an Attenuated Vesicular Stomatitis Virus Encoding the Sodium Iodide Symporter Gene Blood. Oct, 2007 | Pubmed ID: 17515401 Oncolytic Viruses: What's Next? Current Cancer Drug Targets. Mar, 2007 | Pubmed ID: 17346103 Cell-based Delivery of Oncolytic Viruses: a New Strategic Alliance for a Biological Strike Against Cancer Molecular Therapy : the Journal of the American Society of Gene Therapy. Apr, 2007 | Pubmed ID: 17264852 Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity Molecular Therapy : the Journal of the American Society of Gene Therapy. Jan, 2007 | Pubmed ID: 17164783 Novel Therapeutic Target: the PERKs of Inhibiting the Integrated Stress Response Cell Cycle (Georgetown, Tex.). Dec, 2006 | Pubmed ID: 17218786 Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV(deltaM51)) on Multifocal and Invasive Gliomas Journal of the National Cancer Institute. Nov, 2006 | Pubmed ID: 17077357 Matrix Protein of Vesicular Stomatitis Virus Harbours a Cryptic Mitochondrial-targeting Motif The Journal of General Virology. Nov, 2006 | Pubmed ID: 17030873 Perk-dependent Translational Regulation Promotes Tumor Cell Adaptation and Angiogenesis in Response to Hypoxic Stress Molecular and Cellular Biology. Dec, 2006 | Pubmed ID: 17030613 A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-step Desensitization Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2006 | Pubmed ID: 16638865 Internal Ribosome Entry Site-mediated Translation of Apaf-1, but Not XIAP, is Regulated During UV-induced Cell Death The Journal of Biological Chemistry. Jun, 2006 | Pubmed ID: 16595687 Recent Progress in the Battle Between Oncolytic Viruses and Tumours Nature Reviews. Cancer. Dec, 2005 | Pubmed ID: 16294217 Internal Translation Initiation Mediated by the Angiogenic Factor Tie2 The Journal of Biological Chemistry. Jun, 2005 | Pubmed ID: 15802272 Resistance to Vesicular Stomatitis Virus Infection Requires a Functional Cross Talk Between the Eukaryotic Translation Initiation Factor 2alpha Kinases PERK and PKR Journal of Virology. Dec, 2004 | Pubmed ID: 15542627 Vesicular Stomatitis Virus: a Potential Therapeutic Virus for the Treatment of Hematologic Malignancy Human Gene Therapy. Sep, 2004 | Pubmed ID: 15353037 Activating Transcription Factor 4 is Translationally Regulated by Hypoxic Stress Molecular and Cellular Biology. Sep, 2004 | Pubmed ID: 15314157 Vesicular Stomatitis Virus: Re-inventing the Bullet Trends in Molecular Medicine. May, 2004 | Pubmed ID: 15121047 VSV Strains with Defects in Their Ability to Shutdown Innate Immunity Are Potent Systemic Anti-cancer Agents Cancer Cell. Oct, 2003 | Pubmed ID: 14585354 Getting Oncolytic Virus Therapies off the Ground Cancer Cell. Jul, 2003 | Pubmed ID: 12892708 CHD1 Associates with NCoR and Histone Deacetylase As Well As with RNA Splicing Proteins Biochemical and Biophysical Research Communications. Aug, 2003 | Pubmed ID: 12890497 An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress Molecular Cell. Mar, 2003 | Pubmed ID: 12667446 Ex Vivo Infection of Live Tissue with Oncolytic Viruses Jean-Simon Diallo1, Dominic Roy1, Hesham Abdelbary1, Naomi De Silva1, John C. Bell1 1Center for Innovative Cancer Research, Ottawa Hospital Research Institute (OHRI) JoVE 2854 Medicine
Ex Vivo Infection of Live Tissue with Oncolytic Viruses Jean-Simon Diallo1, Dominic Roy1, Hesham Abdelbary1, Naomi De Silva1, John C. Bell1 1Center for Innovative Cancer Research, Ottawa Hospital Research Institute (OHRI) JoVE 2854 Medicine